Masimo upgraded by Raymond James with a new price target
$MASI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Raymond James upgraded Masimo from Mkt Perform to Outperform and set a new price target of $170.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/6/2024 | $170.00 | Mkt Perform → Outperform | Raymond James |
| 6/3/2024 | $126.00 → $160.00 | Neutral → Overweight | Piper Sandler |
| 4/15/2024 | $148.00 → $170.00 | Hold → Buy | Stifel |
| 3/25/2024 | $117.00 → $160.00 | Equal Weight → Overweight | Wells Fargo |
| 1/30/2024 | $107.00 → $121.00 | Buy → Hold | Jefferies |
| 1/3/2024 | Buy → Hold | Needham | |
| 11/8/2023 | Outperform → Mkt Perform | Raymond James | |
| 7/18/2023 | $205.00 → $120.00 | Buy → Hold | Stifel |
4 - MASIMO CORP (0000937556) (Issuer)
4 - MASIMO CORP (0000937556) (Issuer)
4 - MASIMO CORP (0000937556) (Issuer)
8-K - MASIMO CORP (0000937556) (Filer)
8-K - MASIMO CORP (0000937556) (Filer)
10-Q - MASIMO CORP (0000937556) (Filer)
- Reuters Citing CNBC
Highlights Quentin Koffey's Actions That Have Flown in the Face of Good GovernanceMasimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI) today highlighted the actions taken by Politan and Quentin Koffey since Masimo's 2023 Annual Meeting of Stockholders that directly contradict their purported commitment to good governance.Over the past twelve months, we believe Politan's Quentin Koffey has repeatedly acted against the best interests of Masimo and its stockholders. The summary provided below shows stockholders and the public the numerous actions Politan has taken to advance its own agenda at the expense of Masimo's governance and stockholder value.
Third Quarter 2024 Highlights: Healthcare revenue of $343.3 million increased 11.5% on a reported basis and 11.7% on a constant currency basis(1); GAAP net income per diluted share was $0.18; and Non-GAAP(1) net income per diluted share was $0.98. Masimo Corporation (NASDAQ:MASI) today announced its financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Results Consolidated revenue was $504.6 million, comprised of healthcare revenue of $343.3 million and non-healthcare revenue of $161.3 million. Shipments of noninvasive technology boards and instruments were 60,500. GAAP operating income was $30.1 million and non-GAAP(1) operating income was $80.8
Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release third quarter 2024 financial results for the period ended September 28, 2024, after the market closes on Tuesday, November 5, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Michelle Brennan, interim Chief Executive Officer, Micah Young, Executive Vice President and Chief Financial Officer and Bilal Muhsin, Chief Operating Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a re
Highlights Risk to Continued Momentum and Innovation if Politan Gains Board Control Urges Stockholders to Vote "FOR" Only Masimo's Director Nominees, Joe Kiani and Christopher Chavez, on the Updated GOLD Proxy Card Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), a global leader in noninvasive monitoring technologies and audio products, today mailed a letter to stockholders in connection with its upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on September 19, 2024, highlighting the Company's commitment to long-term value creation and the risks to its continued momentum and innovation if Politan were to gain control of the Company's Board of Direct
Masimo (NASDAQ:MASI) today announced that its management will participate in the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:30 a.m. GMT. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ:MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers &
Masimo (NASDAQ:MASI) today announced that its management will participate in the Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 11:30 a.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ:MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bower
Third Quarter 2024 Highlights: Healthcare revenue of $343.3 million increased 11.5% on a reported basis and 11.7% on a constant currency basis(1); GAAP net income per diluted share was $0.18; and Non-GAAP(1) net income per diluted share was $0.98. Masimo Corporation (NASDAQ:MASI) today announced its financial results for the third quarter ended September 28, 2024. Third Quarter 2024 Results Consolidated revenue was $504.6 million, comprised of healthcare revenue of $343.3 million and non-healthcare revenue of $161.3 million. Shipments of noninvasive technology boards and instruments were 60,500. GAAP operating income was $30.1 million and non-GAAP(1) operating income was $80.8
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
Appoints Michelle Brennan as Interim CEO Following Joe Kiani's Decision to Resign Continues to Be Committed to Review of Strategic Alternatives for Consumer Businesses, With Assistance From Leading Financial and Legal Advisors Reaffirms Financial Guidance for Third Quarter 2024 Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI) a leading global medical innovator, provided a series of leadership and business updates: Leadership Appointments Michelle Brennan, a current member of Masimo's Board, has been appointed interim Chief Executive Officer ("CEO") following Chairman and CEO Joe Kiani informing the Board of his decision to resign as CEO. After being elected by shareho
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Raymond James upgraded Masimo from Mkt Perform to Outperform and set a new price target of $170.00
Piper Sandler upgraded Masimo from Neutral to Overweight and set a new price target of $160.00 from $126.00 previously
Stifel upgraded Masimo from Hold to Buy and set a new price target of $170.00 from $148.00 previously
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)